Adaptimmune Therapeutics PLC — Director's Dealing 2016

May 19, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Adaptimmune Therapeutics PLC (ADAP)
CIK: 0001621227
Period of Report: 2016-05-19

Reporting Person: Sigal Charles Elliott (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-05-19	Ordinary Shares with a nominal value of GBP0.001 per share	P	15000	$1.56	Acquired	314100	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Ordinary Shares with a nominal value of GBP0.001 per share	52938	Direct

Footnotes

F1: Dr. Sigal is a manager of Sigal Family Investments, LLC. Dr. Sigal may be deemed to have voting and investment power over the shares held by Sigal Family Investments, LLC. Dr. Sigal disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.

F2: The 15,000 Ordinary Shares are represented by 2,500 American Depositary Shares ("ADSs") which are held by Sigal Family Investments, LLC. Each ADS represents six Ordinary Shares of Adaptimmune Therapeutics plc.

F3: The price of $1.56 per Ordinary Share was derived from the purchase price paid on May 19, 2016, of $9.36 per ADS, divided by six.

F4: The 314,100 Ordinary Shares comprise (i) 254,100 Ordinary Shares, and (ii) 60,000 Ordinary Shares represented by 10,000 ADSs.

F5: The 52,938 Ordinary Shares are represented by 8,823 ADSs.